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AbstrACt
Objectives In cancer studies, the target received dose 
intensity (tRDI) for any regimen, the intended dose and 
time for the regimen, is commonly taken as a proxy for 
achieved RDI (aRDI), the actual individual dose and time 
for the regimen. Evaluating tRDI/aRDI mismatches is 
crucial to assess study results whenever patients are 
stratified on allocated regimen. The manuscript develops 
a novel methodology to highlight and evaluate tRDI/aRDI 
mismatches.
Design Retrospective analysis of a randomised controlled 
trial, MRC BO06 (EORTC 80931).
setting Population-based study but proposed 
methodology can be applied to other trial designs.
Participants A total of 497 patients with resectable high-
grade osteosarcoma, of which 19 were excluded because 
chemotherapy was not started or the estimated dose was 
abnormally high (>1.25 × prescribed dose).
Intervention(s) Two regimens with the same 
anticipated cumulative dose (doxorubicin 6×75 mg/
m2/week; cisplatin 6×100 mg/m2/week) over different 
time schedules: every 3 weeks in regimen-C and every 
2 weeks in regimen-DI.
Primary and secondary outcome measures tRDI 
distribution was measured across groups of patients 
derived from k-means clustering of treatment data. 
K-means creates groups of patients who are aRDI-
homogeneous. The main outcome is the proportion of tRDI 
values in groups of homogeneous aRDI.
results For nearly half of the patients, there is a 
mismatch between tRDI and aRDI; for 21%, aRDI was 
closer to the tRDI of the other regimen.
Conclusions For MRC BO06, tRDI did not predict well 
aRDI. The manuscript offers an original procedure 
to highlight the presence of and quantify tRDI/aRDI 
mismatches. Caution is required to interpret the effect 
of chemotherapy-regimen intensification on survival 
outcome at an individual level where such a mismatch is 
present. The study relevance lies in the use of individual 
realisation of the intended treatment, which depends 
on individual delays and/or dose reductions reported 
throughout the treatment.
trial registration number ISRCTN86294690.
IntrODuCtIOn
In chemotherapy-based treatment of cancer, 
there is substantial interest in relating dose 
escalation of cytostatic-agents and treat-
ment-time compression to the clinical 
outcomes of interest. Treatment intensity 
with respect to both dose and time is gener-
ally summarised using a single measure called 
‘received dose intensity’ (RDI). RDI was first 
described by Hryniuk as the given dose over 
a given time period1; this definition can apply 
to both single cytostatic agents and drug 
combinations.2 The effect of RDI on clinical 
response and survival has been a central issue 
in chemotherapy treatment for more than 30 
years. The prognostic and predictive value 
of high RDI in cancer survivorship has been 
discussed by many authors, including in breast 
cancer,3–5 lymphoma,4 renal cell cancer6 
and pancreatic cancer.7 There might be a 
threshold beyond which further increasing 
DI provides no additional effect.4 8 9 Investi-
gating the relationship between increased 
RDI and improved outcome is complicated 
by the effect of multiple factors.9 
strengths and limitations of this study
 ► The study proposes an innovative method based on 
machine learning.
 ► This method highlights and evaluates potential 
mismatches between intended and achieved treat-
ment-intensity in cancer studies.
 ► The method’s applicability is currently limited to ret-
rospective analyses.
 ► The study contributes to the development of preci-
sion medicine because the method can address the 
relationship between individual dose intensity and 
survival.
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In randomised controlled trials (RCTs), the gold standard 
is to analyse patients according to the treatment regimen to 
which they were allocated, including in trials where the aim 
was to investigate whether increased RDI of chemotherapy 
would improve survival outcome. In dose-response trials, 
the intended cumulative dose and planned treatment dura-
tion together define the tRDI for each regimen. The ratio of 
the actual dose for any given patient and their actual treat-
ment time, that is, the aRDI, may not be the tRDI in prac-
tice. In many situations, tRDI might not be a good predictor 
of aRDI. Depending on the treatment-delivery protocol, 
the relationship between tRDI and aRDI might vary suffi-
ciently that many patients, if reviewed without reference to 
allocated treatment, look to have been treated according 
to the other regimen. This mismatch might be driven, for 
example, by adverse events and unwanted side-effects from 
the allocated treatment.10 11
We examined individual’s treatment data and evaluated 
the extent to which baseline computations of tRDI agree 
with the actual intensity of individual treatments observed, 
that is, aRDI. The aim was to present a method to address 
the relationship between RDI and survival at a personalised 
level. The motivating example was the MRC BO06 RCT for 
patients with osteosarcoma.12 This was a dose-escalation 
trial and therefore was ideal to investigate any mismatch 
between aRDI and tRDI. The two regimens in MRC BO06 
were designed to deliver the same cumulative dosage over 
two-time schedules, and there was concern that clinicians 
would not or could not implement the protocol regimens. 
The efficacy of systemic treatment has been already demon-
strated in osteosarcoma but, in spite of a significant associa-
tion between high RDI and short-term clinical response, no 
long-term survival improvement had been demonstrated 
from treatment intensification.13 14
PAtIents AnD methODs
Patients
The data for our study were obtained, by formal data 
release request, from the MRC-BO06/EORTC-80931 RCT 
for patients with non-metastatic high-grade osteosarcoma 
which recruited between 1993 and 2002. The trial 
randomised patients between conventional treatment 
with doxorubicin (DOX) and cisplatin (CDDP) given 
every 3 weeks (regimen-C) versus a dose-intense regimen 
of the same two drugs given every 2 weeks (regimen-DI), 
supported by granulocyte colony-stimulating factor. 
Chemotherapy was administered for six cycles (a cycle is a 
period of either 2 or 3 weeks depending on the allocated 
regimen), before and after surgical removal of the primary 
osteosarcoma. In both the conventional (C) and dose-in-
tense arms, DOX (75 mg/m2) plus CDDP (100 mg/m2) 
were given over six cycles. Surgery to remove the primary 
tumour was scheduled at week 6 after starting treatment 
in both arms, that is, after 2×DOX+ CDDP in regimen-C 
and after 3×DOX+ CDDP in regimen-DI. Postoperative 
chemotherapy was intended to resume 3 weeks after 
surgery in both arms; figure 1 shows the trial design. The 
trial reported on the association between levels of tumour 
necrosis observed at surgery—also known as histological 
response—and survival. Additional details can be found 
in the primary analysis of the trial.12
The received dataset included 497 eligible patients. We 
excluded a further 19 patients who did not start chemo-
therapy (13) or reported an abnormal dosage of one or 
both agents (six; given dose >1.25 × prescribed dose).
Patient involvement
There was no patient or public involvement in the original 
RCT, which was run before this was recognised as good 
practice, nor in this study; patient and public involvement 
is not common in methodological studies.
Calculating target and achieved rDI
Both tRDI and aRDI are computed according to the 
ratio δ/τ, where δ is the standardised cumulative dose 
and τ is the standardised time-on-treatment15; δ and τ 
are computed for the allocated regimen for tRDI (ie, 
two pairs of values, one for each arm). For aRDI, δ and τ 
are computed for each specific subject by using patients’ 
treatment-data.
Figure 1 Patients are randomised at baseline to one of the two regimens, with identical anticipated cumulative dose but 
different duration.
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The standardised cumulative dose, δ, is computed by 
averaging single-agent standardised cumulative dose, that 
is, δ=0.5 × (δDOX + δCDDP). Single-agent cumulative doses, 
standardised by body surface area (BSA) which is a func-
tion of height and weight, are computed according to 
δAGENT = ∑CYCLE (dAGENT, CYCLE/BSACYCLE)/(6×planned dose 
of agent), where cycle is each cycle of two-drug chemo-
therapy, d is the given dose of agent in mg, BSACYCLE is the 
patient’s body surface area at the beginning of cycle and 
the sum is over the six cycles; the planned dose of agent 
is in mg/m2. In case agent is omitted or treatment discon-
tinued, dAGENT, CYCLE = 0 for all omitted/discontinued cycle.
The standardised time-on-treatment, τ, is defined as 
the difference in days between the starting dates of the 
first and the last cycle reported on the case report form 
(including the surgery window which was taken to be 21 
days), divided by the intended duration of regimen-DI. 
In this way, we are considering the intensity of individual 
treatments relative to the anticipated DI regimen.16 The 
intended duration of both regimens was computed as: 
(5×14)+21 + 1=92 days for regimen-DI, and (5×21)+21 + 
1=127 days for regimen-C, which is a difference of 35 days.
In general, any two patients—even two regimen-C or 
two regimen-DI patients—will report different values of 
τ and δ depending on the individual realisation of their 
intended treatment, that is, depending on the delays and 
dose reductions required during chemotherapy due to 
toxicity.
According to the definitions above, we expect similar 
values of δ but different values of τ. As the difference in 
the planned duration between the regimens is 35 days, 
we expect a difference of about 35/92=0.38 between the 
τ of a regimen-C and a regimen-DI patient, that is, the 
tRDI for regimen-DI is 1.00 and tRDI for regimen-C is 
1.00/1.38=0.72.
Displaying of treatment data: the time–dose plane
Graphical techniques are used to visualise how treat-
ments were administered with respect to cumulative dose 
reductions and cumulative delays. We draw patients in 
the time–dose plane, also called τδ-plane, (see figure 2). 
In this plane, each patient is represented by a point: the 
x-coordinate is the standardised time-on-treatment, τ 
and the y-coordinate is the standardised cumulative dose 
received, δ. For patients who completed all six anticipated 
cycles, the quantity δ/τ is close to the achieved RDI as 
defined by Lewis.15
statistical methods
Groups of patients with similar aRDI were identified by 
k-means clustering17 (unsupervised machine learning) 
and plotted on the time–dose (τδ) plane. Patients lying 
close to each other on the τδ-plane reported similar 
cumulative doses in a similar time span and therefore 
they have a similar aRDI.
Figure 2 Scatterplot of standardised dose verses standardised time coloured by intended regimen. The ratio δ/τ is the 
achieved received dose intensity (RDI), which graphically corresponds to the slope of a line joining the patient with the point 
of coordinates (0,0), that is, a fictitious patient that never initiated treatment. For patients that completed the protocol, the 
achieved RDI is practically equivalent to the RDI computed by Lewis et al.15
 o
n
 7 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022980 on 30 May 2019. Downloaded from 
4 Lancia C, et al. BMJ Open 2019;9:e022980. doi:10.1136/bmjopen-2018-022980
Open access 
We evaluated any mismatch between tRDI and aRDI by 
looking at the distribution of tRDI across the aRDI-ho-
mogeneous patient groups (the clusters); the number 
of groups, k, was progressively increased. The precision 
achieved by a specific cluster was the largest between 
the proportion of regimen-C and regimen-DI patients 
contained in that group. We evaluate the clustering 
result at different values of k by computing homoge-
neity, completeness and V-measure18 given the individual 
intended regimen. Homogeneity and completeness 
both ranged between 0 and 1. A larger value of homo-
geneity indicated that groups tended to be formed by 
patients randomised to the same regimen. In particular, 
high homogeneity yields high precision in all clusters. A 
high completeness score means that patients randomised 
to the same regimen belonged to the same cluster. The 
V-measure was the harmonic mean of homogeneity 
and completeness. The implementation of k-means was 
provided by Python V.3.6.3 library scikit-learn.19
results
Individual treatment data and presence of t/arDI mismatch
Summary measures of standardised time on treatment, τ 
and mean cumulative dose, δ, are illustrated in table 1. As 
expected, regimen-C and regimen-DI show similar distri-
butions of the average cumulative dose, δ. The mean 
difference in τ between regimen-C and regimen-DI is 0.21, 
which corresponds to approximately 3 weeks (0.21×92 = 
19 days), while the median difference is slightly larger 
(0.24×92 = 22 days). The primary analysis of MRC BO0612 
already noted a smaller-than-anticipated difference in the 
median values, which was expected to be 5 weeks. The 
IQR of τ for regimen DI (from 1.07×92 = 98 to 1.35×92 
= 124 days) has limited overlap with that of regimen-C 
(from 1.34×92 = 123 to 1.60×92 = 147 days). The IQR, by 
definition, contains the central 50% of observed times, 
therefore implying that 25% of regimen-DI patients 
completed treatment in more than 124 days, that is, in a 
period closer to the target median-duration of regimen-C 
than the target median duration of regimen-DI. On the 
other hand, 25% of regimen-C patients completed treat-
ment in less than 123 days, that is, in a period that is closer 
to the target median duration of regimen-DI than to the 
target median-duration of regimen-C. Figure 3 shows 
the distribution of single-drug standardised cumulative 
doses (figure 3; left and central panels) and standardised 
time-on-treatment (figure 3; right panel), stratified by the 
intended regimen.
Figure 2 shows a scatter plot of τ and δ. DI-patients are 
depicted as pink circles, while C-patients are represented 
by purple squares. Since pink and purple points are not 
horizontally separated, it would be difficult to distinguish 
Table 1 Statistical properties of standardised time-on-treatment (τ) and cumulative dose (δ)
Mean SD Min Median IQR Max
Regimen-C (n=235) τ 1.36 0.47 0.00 1.464 (1.34, 1.60) 2.99
δ 0.84 0.22 0.17 0.94 (0.78, 1.00) 1.06
Regimen-DI (n=243) τ 1.15 0.35 0.00 1.22 (1.07, 1.35) 1.93
δ 0.87 0.19 0.17 0.96 (0.82, 1.00) 1.06
The reference value of τ is 1, which corresponds to 84 days, that is, the planned duration of regimen-DI. The reference value of δ is 1, which 
corresponds to 450 mg/m2 of doxorubicin plus 600 mg/m2 of cisplatin.
Figure 3 Violin plot of both single-agent standardised doses and standardised time. A violin plot combines features of a 
boxplot to features of a histogram in the same figure. The central candlestick has three components: the thick part displays 
the IQR, the white dot the median, and the thin vertical lines the whiskers of a boxplot. On both sides of the candlestick lies a 
smoothed histogram (regimen-C on the left and regimen-DI on the right). When the violin is symmetric, then the distribution of 
the quantity is the same in both regimens. This is true for the first two panels (δDOX and δCDDP), but not for the rightmost (τ). Yet, 
the two halves of the violin of τ do overlap for a substantial part, reflecting the findings of table 1. Patients who discontinued 
after the first cycle are present. For these patients, τ=0 and consequently, the support of the violin of τ extends to negative 
values.
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many of the regimen-DI and regimen-C patients if we were 
to draw again figure 2 with a single colour and a single 
marker. This shows that there was variability in how each 
regiment was delivered (ie, a t/aRDI-mismatch) because 
the correspondence between intensity of intended and 
delivered treatment is commonly confused.
Analysis of clustering results and evaluation of t/arDI 
mismatch
Figure 4A–D shows results with 2, 3, 4 and 5 clusters, 
regardless of allocated treatment, that is, four groupings 
of patients in the τδ-plane. Groups are labelled with a 
progressive index starting from 0. With more clusters, 
we achieve a more detailed grouping: with only 2 or 3 
clusters, the clustering is based more on separation in δ, 
that is, based on similarity of dose-reductions only; with 
4 or 5 clusters, the biggest group of patients with the 
highest cumulative dose (cluster 0 in figure 4A and B) is 
split around τ=1.5, that is, about 135 days. By increasing 
k, we can obtain at least one cluster where we can find a 
majority for regimen-C patients and one with a majority 
of regimen-DI patients. The precision achieved within 
each cluster is reported in table 2 together with the 
median values of standardised cumulative dose and time-
on-treatment, number of cycles completed and individual 
aRDI computed as in Ref.15 For all values of k, figure 5 
summarises individual aRDI values in each patient group; 
each boxplot refers to the corresponding clustering result 
shown in figure 4.
Table 3 shows homogeneity, completeness and V 
measure for each value of k. The clustering result shows 
the highest scores for k=4. This yields a grouping where 
clusters are the most homogeneous, that is, patients in the 
same group tend to share the same intended treatment, 
and the most complete, that is, patients randomised to 
the same regimen lie in the same cluster. We can interpret 
the clustering results as follows.
Using only two or three clusters, we achieve balanced 
groups with nearly the same proportion of regimen-C and 
regimen-DI patients because the stratification is based on 
dose reductions, and these have very similar patterns in 
the two regimens.
Using four clusters, we achieve a precision of 80% and 
70% in the two groups with the highest cumulative dose 
reported, that is, cluster 0 and cluster 3. Although these 
ideally correspond to regimen-C (cluster 0) and regi-
men-DI (cluster 3), there are 27+63= 100 patients (21% 
of sample) who reported an aRDI closer to the tRDI of the 
regimen they were not randomised to. The remaining 2 
groups contain 57+76 = 133 patients (28% of the sample) 
and achieve a precision of about 50%–55%, that is, each 
contains about the same amount of regimen-C and regi-
men-DI patients. According to table 2, cluster 1 and 
cluster 2 can be interpreted as early treatment-discontin-
uations and treatments completed with major reductions, 
respectively.
With five clusters (figure 4D), we achieve similar preci-
sion to four clusters in that two groups with highest 
Figure 4 Clustering result for different values of the desired number of clusters, k. Size, composition, precision and median 
values of quantities of interest are reported for each cluster and each value of k by table 2. For each of the four clustering 
results, figure 5 summarises the individual values of received dose intensity computed according to Lewis et al.15
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cumulative dose (cluster 0 and cluster 3), while the 
remaining clusters again achieve a precision around 
50%. However, by using five clusters, it is easier to iden-
tify groupings of patients who did not complete the 
allocated regimen. According to table 2, the remaining 
three clusters can be interpreted as follows: cluster 1: 
group of patients with early treatment-discontinuations, 
cluster 2: group of patients with late discontinuations and 
cluster 4: group of patients with full treatment with major 
reductions.
Results shown in table 2 and figure 4 suggest that four 
clusters (k=4) is the most appropriate choice: it has the 
advantage of returning higher precision than k=3 and 
not returning very small clusters like k=5. In conclusion, 
k=4 seemed to be the optimal number of groups for the 
MRC BO06 dataset. This method suggested that tRDI 
Table 2 Precision of the clustering results and median values of standardised cumulative dose, standardised time-on-
treatment, number of cycles completed and received dose intensity (RDI) computed according to Lewis et al15
Cluster label N. pts. N. Reg-C N. Reg-DI Precision (%) δ τ N. cycles RDI
k=2 Cluster 0 407 201 206 51 0.97 1.38 6 0.62
Cluster 1 71 34 37 52 0.47 0.35 3 0.31
k=3 Cluster 0 319 152 167 52 1.00 1.38 6 0.65
Cluster 1 57 29 28 51 0.33 0.29 2 0.25
Cluster 2 102 54 48 53 0.78 1.34 6 0.48
k=4 Cluster 0 135 108 27 80 0.95 1.60 6 0.55
Cluster 1 57 29 28 51 0.33 0.29 2 0.25
Cluster 2 76 35 41 54 0.75 1.30 6 0.49
Cluster 3 210 63 147 70 1.00 1.29 6 0.71
k=5 Cluster 0 210 62 148 70 1.00 1.28 6 0.71
Cluster 1 46 25 21 54 0.33 0.24 2 0.24
Cluster 2 31 12 19 61 0.64 0.84 4 0.42
Cluster 3 114 90 24 79 0.98 1.60 6 0.55
Cluster 4 77 46 31 60 0.79 1.42 6 0.49
Figure 5 Individual received dose intensity (computed according to Lewis et al15) in groups obtained by clustering patients in 
the τδ-plane.
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seems to have had small to no predictive ability for 28% 
of patients. Moreover, there was an additional 21% of 
patients, belonging to cluster 0 or cluster 3, that showed 
some evidence of an RDI mismatch because their indi-
vidual aRDI is closer to the tRDI of the other regimen.
DIsCussIOn
Our principal finding is that tRDI did not seem to be 
a good predictor for aRDI in the MRC BO06 dataset. 
In order to explore this, we have proposed a machine-
learning powered method for quantifying the correspon-
dence between tRDI and aRDI. We illustrated the method 
within the context of osteosarcoma treatment because 
this is an application of great potential interest. In osteo-
sarcoma, increased RDI is associated with higher levels 
of tumour necrosis—which are known to decrease the 
hazard of survival outcome13 14—yet increased RDI does 
not translate to improved survivorship.20–22 Our results 
indicate that distinguishing regimen C from regimen DI 
patients by simply looking at their cumulative dose and 
time on treatment is often not possible because of t/
aRDI mismatch (figure 2): many patients received their 
allocated regimen yet lie closer to the aRDI observed for 
patients randomised to the other arm. From the point 
of view of aRDI and its effect on survival outcome, they 
could be thought of as treatment switches. Finally, we 
identified in the original cohort four groups (figure 4, 
bottom left panel) that capture groupings of treatment 
discontinuations, major reductions, treatment comple-
tions and treatment completions over a longer time. The 
analysis of these groups revealed that for 49% of patients, 
tRDI was not a good predictor of aRDI. Even considering 
treatment completions only, the mismatch is still very 
high (21%).
This study discusses the use of individual realisations 
of the intended treatment, which depends on delays 
and dose reductions reported throughout the course 
of treatment. A novel method to estimate the potential 
intended/achieved-treatment mismatch is illustrated. 
The method can be applied to other randomised clinical 
trials (see online supplementary appendix for details). 
The mismatch is more likely to arise when the arms of the 
trial have a similar design. More research is required to 
investigate the presence of mismatch between achieved 
and target RDI in a prospective way. This method would 
be a helpful tool at interim analyses: if treatments are 
looking muddled, then the trial is going to be difficult 
to interpret and the investigators might wish to take early 
action.
The relationship between RDI and long-term cancer 
survivorship is usually addressed by stratifying patients on 
the allocated regimen. The method proposed in this manu-
script keeps dose and time apart while guaranteeing that 
interpretation of the results in terms of aRDI is still possible. 
However, compared with classical stratification at baseline, 
the method proposed here forms groups of similar aRDI 
which are no longer randomised. While this fact does not 
impact the capability of the method of highlighting a/tRDI 
mismatches, covariate rebalancing23 might be required in 
order to address other clinical research questions.
When investigating the association between doses and 
survival outcomes, it is crucial to address departure of indi-
vidual, observed RDI values from those anticipated. In the 
particular case of MRC BO06, we have shown that a substan-
tial proportion of regimen-C and regimen-DI patients cannot 
be distinguished based on the reported treatment-intensity. 
Since MRC-BO06 was an RCT, any difference we may find in 
the survival curves for regimen-DI and regimen-C must be 
associated with tRDI. However, had the BO06 study found 
that regimen-DI survive better, we might erroneously claim 
that higher aRDI is associated to better survival. In other 
words, we could think we can support individual regimen 
compression. However, this is not guaranteed if tRDI and 
aRDI are not the same.
For this reason, we recommend the use of the proposed 
method in exploratory analyses and we put a call on all 
relevant stakeholders to amend their statistical analysis 
plans.
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